Generic Medicine Info
Indications and Dosage
Adult: 50-600 mg daily. Resistant cases: Up to 1,000 mg daily. May also be given intramuscularly.
Hepatic Impairment
Dose reduction may be required.
Coma, CNS depression.
Special Precautions
Severe liver and kidney dysfunction, phaeochromocytoma, breast cancer, Parkinson's disease, depression, pronounced changes in BP, orthostatic dysregulation, glaucoma, urinary retention, enlarged prostate, intestinal obstruction, history of convulsions, chronic respiratory symptoms, asthma, leukopenia, coronary heart disease, excitation conduction disorders or arrhythmias, blood dyscrasias. Monitor haematological parameters on prolonged use. May impair ability to drive or operate machinery. Pregnancy and lactation.
Adverse Reactions
Acute neuropathy of the superficial nerve fibres after exposure to the sun. Fatigue, haematological disturbances, mood disorders, breast tenderness, galactorrhoea, amenorrhoea, circulatory failure, nosebleeds, photosensitivity, rash, sleep disturbances, anxiety, oedema of the legs, intestinal inflammation.
Potentially Fatal: Severe hepatic impairment (high doses).
Drug Interactions
Additive CNS depression with sedatives, tranquillisers, alcohol and other CNS depressants. May increase the effects of antihypertensive agents and epinephrine. May reduce effects of guanethidine, clonidine, levodopa. May potentiate the adverse effects of other anticholinergic drugs e.g. TCAs. Extrapyramidal symptoms may be increased.
Description: Perazine is a phenothiazine antipsychotic agent.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Perazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in